Clinical inputs
Understand the result,
not just the number.
CHOP/Anthracycline Cumulative Dose Score: Explanation and Clinical Context The CHOP/Anthracycline Cumulative Dose Score estimates the risk of anthracycline-induced cardiotoxicity by calculating the total doxorubicin-equivalent dose from different anthracycline drugs, including doxorubicin, daunorubicin, and epirubicin. Conversion factors are applied to account for differences in cardiotoxic potential: daunorubicin × 0.833 and epirubicin × 0.5 to obtain doxorubicin-equivalent doses. Risk stratification is based on cumulative dose thresholds: <250 mg/m² (low risk), 250–400 mg/m² (moderate risk), >400 mg/m² (high risk).
This tool helps clinicians anticipate cardiotoxicity risk, plan cardiac monitoring, and adjust chemotherapy dosing.
- Source 1
Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-2879. doi:10.1002/cncr.11407
Loading discussion…